IL17A and psoriasis: IL-17 inhibitors, including secukinumab, brodalumab, and ixekizumab, have been approved for treating moderate-to-severe psoriasis and assessed for non-psoriatic uses, such as hidradenitis suppurativa and alopecia areata (63).